Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
10/2000
10/05/2000WO2000058334A1 50 human secreted proteins
10/05/2000WO2000058307A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057877A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
10/05/2000CA2368951A1 50 human secreted proteins
10/05/2000CA2368700A1 49 human secreted proteins
10/05/2000CA2368631A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
10/05/2000CA2368467A1 50 human secreted proteins
10/05/2000CA2368281A1 50 human secreted proteins
10/05/2000CA2366305A1 Method for expressing proteins
10/05/2000CA2365401A1 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/04/2000EP1041072A1 Dioxocyclopentyl hydroxamic acids
10/04/2000EP1040822A1 Extensible Mask with an adhesive matrix which is at least stretchable when wetted
10/04/2000EP1040183A1 Nucleic acid encoding mammalian ubr1
10/04/2000EP1039929A1 Activated t-cells and their uses
10/04/2000EP1039893A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
10/04/2000CN1057013C Novel 1 L-2 receptor-specific human immunoglobins
10/04/2000CN1056989C External use medicine for traumatic injuries
09/2000
09/28/2000WO2000056891A2 Human transmembrane proteins
09/28/2000WO2000056862A1 Human tumor necrosis factor receptor tr9
09/28/2000WO2000056772A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000WO2000056767A1 46 human secreted proteins
09/28/2000WO2000056755A1 49 human secreted proteins
09/28/2000WO2000056754A1 48 human secreted proteins
09/28/2000WO2000056738A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000WO2000056729A1 Chemokine recpetor binding heterocyclic compounds
09/28/2000WO2000056374A1 Muscle tissue engineering
09/28/2000WO2000056356A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000WO2000041545A3 Regulators of the pct or smoothened pathway, compositions and uses related thereto
09/28/2000WO2000040693A3 Expression of secreted human alpha-fetoprotein in transgenic animals
09/28/2000WO2000022143A3 Protein kinase homologs
09/28/2000WO2000022142A3 Cell signaling polypeptides and nucleic acids
09/28/2000WO2000015793A3 Human gpcr proteins
09/28/2000CA2669512A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367132A1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000CA2366931A1 Muscle tissue engineering
09/28/2000CA2366691A1 48 human secreted proteins
09/28/2000CA2365255A1 Human tumor necrosis factor receptor tr9
09/28/2000CA2365247A1 49 human secreted proteins
09/28/2000CA2365243A1 Human transmembrane proteins
09/28/2000CA2365223A1 46 human secreted proteins
09/27/2000EP1038538A1 Muscle tissue engineering
09/27/2000EP1037612A1 Pharmaceutical compositions containing micronized bicyclic drugs
09/27/2000CN1268136A Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
09/27/2000CN1267545A Medicine for injury pain and its preparation
09/26/2000US6124360 Solid compositions suitable for oral administration comprising non hygroscopic salts of L-carnitine and alkanoyl-L-carnitine with 2-aminoethanesulfonic acid
09/26/2000US6124321 An enzyme inhibitor for enhancing memory or treating or preventing alzheimer's disease
09/21/2000WO2000055332A2 Human regulators of intracellular phosphorylation
09/21/2000WO2000055155A2 Heterocyclic compounds as adenosine deaminase inhibitors
09/21/2000WO2000055144A1 Amine derivatives as protease inhibitors
09/21/2000WO2000055127A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3
09/21/2000WO2000055126A2 N-cyanomethylamides as protease inhibitors
09/21/2000WO2000055125A2 N-cyanomethyl amides as protease inhibitors
09/21/2000WO2000054763A2 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone
09/21/2000WO2000054729A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues
09/21/2000WO2000040716A3 Soluble receptor br43x2 and methods of using them for therapy
09/21/2000CA2368148A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2368122A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2367862A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3
09/21/2000CA2367461A1 Heterocyclic aromatic compounds useful as growth hormone secretagogues
09/21/2000CA2367352A1 Amine derivatives as protease inhibitors
09/21/2000CA2364739A1 Regulators of intracellular phosphorylation
09/21/2000CA2332767A1 Dhea composition and method
09/20/2000EP1036195A1 Short gcg expansions in the pab ii gene for oculopharyngeal muscular dystrophy and diagnostic thereof
09/20/2000EP1035824A1 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
09/19/2000US6121375 Gels formed by the interaction of poly(aldehyde) with various substances
09/19/2000US6121319 Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
09/19/2000US6121280 Azabicyclic rotomase inhibitors
09/14/2000WO2000053729A2 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
09/14/2000WO2000053218A1 Neurodegenerative disorder related gene
09/14/2000WO2000037422A3 Ion channel modulating agents
09/14/2000WO2000031263A3 Gtpase associated proteins
09/14/2000WO1999063999A8 H1-histamine receptor antagonists
09/14/2000WO1999033836A9 3'-epimeric k-252a derivatives
09/14/2000DE19910044A1 Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff Viral particles released after infection by human cytomegalovirus and their use as a vaccine
09/14/2000CA2365903A1 Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine
09/13/2000EP1034164A1 Substituted beta-alanine derivatives as cell adhesion inhibitors
09/13/2000CN1266368A Heterocyclic vinylethers against neurological disorders
09/12/2000US6117908 Use of GABAB receptor agonists as reflux inhibitors
09/12/2000US6117445 Administration of an a1 adenosine receptor antagonist, or p2x purinoceptor or a compination of both offer potential as an antifibrotic or antisclerotic treatment
09/08/2000WO2000052210A2 Methods for targeting rna molecules
09/08/2000WO2000051604A1 Intermittent claudication remedies
09/08/2000WO2000029583A3 Immunoglobulin superfamily proteins
09/08/2000WO2000012720A3 Elongase genes and uses thereof
09/08/2000WO1999034784A3 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
09/08/2000CA2373463A1 Intermittent claudication remedies
09/08/2000CA2363077A1 Methods for targeting rna molecules
09/06/2000EP1032667A2 A33-related antigens and their pharmacological uses
09/06/2000EP1032570A1 Isoquinoline derivatives and their therapeutical use
09/06/2000EP1032403A1 Nutritional supplement for cerebral metabolic insufficiencies
09/06/2000EP1032402A1 Citicoline to treat motor neuron diseases and demyelinating diseases
09/06/2000EP1032393A1 QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
09/06/2000EP1032387A1 Novel metal complexes
09/06/2000CN1265647A Acrylic metalloprotease inhibitor
09/06/2000CN1265600A Cloning pigs using donor nuclei from differentiated cells
08/2000
08/31/2000WO2000050872A2 A system for cell-based screening
08/31/2000WO2000050641A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
08/31/2000WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease
1 ... 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 ... 233